Martin F Hentemann

USPTO Granted Patents = 19 (Patent Applications = 3)

CIPO Patents = 3

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 10.2

ph-index = 5

Forward Citations = 110(Granted Patents)

Location History:

Hamden, CT (US) (2008 - 2011)
Lafayette, CO (US) (2013)
Carlisle, CT (US) (2013)
Boulder, CO (US) (2012 - 2016)
Carlisle, MA (US) (2012 - 2018)

Company Filing History:

Bayer Pharmaceuticals Corporation

Bayer Intellectual Property Gmbh

where one patent can have more than one assignee

Years Active: 2008-2018

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. RE46856 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2018-05-21),

2. 9409886 - Pyrimidyl cyclopentanes as AKT protein kinase inhibitors (2016-08-09),

3. 9346805 - Pyrimidyl cyclopentanes as Akt protein kinase inhibitors (2016-05-24),

4. 9328091 - 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors (2016-05-03),

5. 8895566 - 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors (2014-11-25),

6. 8859572 - Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis (2014-10-14),

7. 8618097 - Pyrimidyl cyclopentanes as AKT protein kinase inhibitors (2013-12-31),

8. 8466283 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2013-06-18),

9. 8329709 - 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors (2012-12-11),

10. 8324221 - Pyrimidyl cyclopentanes as Akt protein kinase inhibitors (2012-12-04),

11. 7964622 - Indole acetic acid derivatives and their use as pharmaceutical agents (2011-06-21),

12. 7906653 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation (2011-03-15),

13. 7803956 - Benzofuran derivatives useful for treating hyper-proliferative disorders (2010-09-28),

14. 7714004 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation (2010-05-11),

15. 7678804 - Pyrimidine derivatives for treatment of hyperproliferative disorders (2010-03-16),

Title: The Innovations of Martin F. Hentemann

Introduction

Martin F. Hentemann, based in Boulder, Colorado, is a prolific inventor with a remarkable portfolio of 19 patents. His contributions to the field of pharmaceuticals, specifically in the treatment of hyper-proliferative disorders and diseases associated with angiogenesis, have made significant strides in modern medicine.

Latest Patents

Among his latest inventions, Hentemann has developed novel substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives. These compounds are aimed at treating hyperproliferative disorders by acting as phosphatidylinositol-3-kinase (PI3K) inhibitors. This innovative approach showcases his commitment to advancing treatment options for diseases linked to PI3K activity. Another noteworthy patent includes pyrimidyl cyclopentanes as AKT protein kinase inhibitors, which provide methods for utilizing these compounds in treating hyperproliferative diseases such as cancer.

Career Highlights

Throughout his career, Martin F. Hentemann has worked with notable companies, including Array Biopharma Inc. and Bayer Pharmaceuticals Corporation. His professional journey reflects a strong dedication to research and the development of effective therapeutic agents.

Collaborations

Hentemann has collaborated with distinguished colleagues, such as James F. Blake and Josef R. Bencsik. These partnerships are instrumental in fostering innovation and enhancing the research outcomes of his projects.

Conclusion

Martin F. Hentemann stands out as an accomplished inventor dedicated to addressing critical medical challenges. His innovative patents not only highlight his expertise in the pharmaceutical field but also contribute valuable solutions to improve patient care and treatment efficacy.

This text is generated by artificial intelligence and may not be accurate.